» » »

Cancer Drug Responses Cary NC

new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Andrew Scott Kennedy, MD
(919) 854-4588
300 Ashville Ave Ste 110
Cary, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Loma Linda Univ Sch Of Med, Loma Linda Ca 92350
Graduation Year: 1991

Data Provided by:
William R Berr, MR
(919) 852-1994
218 Ashville Ave Ste 20
Cary, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Scott Lee Sailer, MD
(919) 854-4588
300 Ashville Ave Ste 110
Cary, NC
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Harvard Med Sch, Boston Ma 02115
Graduation Year: 1984

Data Provided by:
Sunil J Desai, MD
(919) 233-0059
300 Keisler Dr Ste 204
Cary, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Municipal Med Coll, Gujarat Univ, Ahmedabad, Gujarat, India
Graduation Year: 1983

Data Provided by:
Kim M Boerick, MD
1001 Winstead Dr Ste 200
Cary, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Mark L Graham
(919) 233-8585
300 Ashville Ave
Cary, NC
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Mark L Graham II, MD
(919) 966-4431
Cary, NC
Specialties
Internal Medicine, Medical Oncology
Gender
Male
Education
Medical School: Mayo Med Sch, Rochester Mn 55905
Graduation Year: 1982
Hospital
Hospital: University Of North Carolina H, Chapel Hill, Nc
Group Practice: Cary Oncology

Data Provided by:
Cassandra N Moore
(919) 854-6900
216 Ashville Ave
Cary, NC
Specialty
Hematology / Oncology

Data Provided by:
Mark L Graham, MD
(919) 233-8585
300 Ashville Ave Ste 180
Cary, NC
Specialties
Internal Medicine, Medical Oncology
Gender
Male
Education
Medical School: Mayo Med Sch, Rochester Mn 55905
Graduation Year: 1982

Data Provided by:
A Bartlett Pandite, MD
Cary, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Liverpool, Fac Of Med, Liverpool, Uk (352-06 Prior 1/71)
Graduation Year: 1983

Data Provided by:
Data Provided by:

Cancer Drug Responses

Provided By:

A new way to predict which brain cancer patients will respond to the drug Avastin has been developed by U.S. researchers.

Avastin, which shrinks tumors by cutting off their blood supply, was approved this spring by the U.S. Food and Drug Administration for treatment of aggressive brain cancer. However, half of those with the cancer don't respond to the drug, which can cost up to $10,000 a month, according to a news release from the University of California, Los Angeles.

UCLA researchers examined 82 people who had surgery and radiation to treat glioblastoma, the most common and deadly form of adult brain cancer. Half of them were given infusions of Avastin every two weeks, and all had monthly MRI brain scans to monitor changes.

An analysis of the scans showed that there was greater water movement in the tumors of people who later had the best response to Avastin. By using MRI to measure the amount of water motion within the tumor, the researchers were able to predict with 70 percent accuracy which tumors would progress within six months and which would not.

Increased water movement in tumors is linked with higher levels of a growth factor called VEGF, which is secreted by a tumor to promote the growth of new blood vessels that provide the tumor with oxygen and nutrients. Avastin blocks VEGF, the researchers explained.

"When we realized that high levels of VEGF are linked to greater cell death and increased water movement, we were able to predict the patients' response to Avastin before they began treatment," lead author Dr. Whitney Pope, assistant professor of radiological sciences at UCLA's David Geffen School of Medicine, said in the news release.

"We were correct 70 percent of the time," Pope said. "Previously, identifying which patients would respond was like flipping a coin. This is a huge improvement."

The study appears in the July issue of Radiology.

"Knowing this information ahead of time will help doctors personalize therapy for each patient and decrease exposure to side effects," Pope said.

He and a co-author are consultants for Genentech, which makes Avastin, and are working with the company on several research studies.

More information

The U.S. National Cancer Institute has more about brain tumors.

SOURCE: University of California, Los Angeles, news release, July 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com